about
A novel educational strategy targeting health care workers in underserved communities in Central America to integrate HIV into primary medical careAcute meningoencephalitis due to human immunodeficiency virus type 1 infection in 13 patients: clinical description and follow-upTrends in Transmission of Drug Resistance and Prevalence of Non-B Subtypes in Patients with Acute or Recent HIV-1 Infection in Barcelona in the Last 16 Years (1997-2012)Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America.Early skewed distribution of total and HIV-specific CD8+ T-cell memory phenotypes during primary HIV infection is related to reduced antiviral activity and faster disease progressionTowards full citizenship: correlates of engagement with the gender identity law among transwomen in Argentina.Use of third line antiretroviral therapy in Latin AmericaDynamics of adrenal steroids are related to variations in Th1 and Treg populations during Mycobacterium tuberculosis infection in HIV positive personsHost genetic factors associated with symptomatic primary HIV infection and disease progression among Argentinean seroconverters.Routine HIV testing among hospitalized patients in Argentina. is it time for a policy change?Tuberculosis in antiretroviral treatment programs in lower income countries: availability and use of diagnostics and screening.Acute HIV seroconversion presenting with active tuberculosis and associated with high levels of T-regulatory cellsTh17 and Th17/Treg ratio at early HIV infection associate with protective HIV-specific CD8(+) T-cell responses and disease progressionComprehensive analysis of unique cases with extraordinary control over HIV replication.Central nervous system opportunistic infections in developed countries in the highly active antiretroviral therapy era.Improving Adherence to Care Among "Hard to Reach" HIV-Infected Patients in Argentina.Early Gag immunodominance of the HIV-specific T-cell response during acute/early infection is associated with higher CD8+ T-cell antiviral activity and correlates with preservation of the CD4+ T-cell compartment.Patient-provider perceptions on engagement in HIV care in Argentina.Mobility and HIV in Central America and Mexico: a critical review.Update on antiretroviral treatment during primary HIV infection.[Advances in the diagnosis and treatment of acute human immunodeficiency virus type 1 (HIV-1) infection].HIV-TB coinfection impairs CD8(+) T-cell differentiation and function while dehydroepiandrosterone improves cytotoxic antitubercular immune responses.ICOS, SLAM and PD-1 expression and regulation on T lymphocytes reflect the immune dysregulation in patients with HIV-related illness with pulmonary tuberculosis.Immunoendocrine interactions during HIV-TB coinfection: implications for the design of new adjuvant therapies.[Lopinavir/ritonavir in new initial antiretroviral treatment strategies].Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the ranTreatment as prevention: are Argentinean HIV care providers willing to adopt earlier antiretroviral therapy?The coughing patient: TB or not TB; that is the question.Prevalence of dihydropteroate synthase genotypes before and after the introduction of combined antiretroviral therapy and their influence on the outcome of Pneumocystis pneumonia in HIV-1-infected patients.Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality.Use of darunavir and enfuvirtide in a pregnant woman.Prevalence of transmitted antiretroviral resistance and distribution of HIV-1 subtypes among patients with recent infection in Catalonia (Spain) between 2003 and 2005.Avances en el diagnóstico y tratamiento de la infección aguda por el VIH-1Tratamiento antirretroviral en pacientes con inmunodeficiencia avanzadaCaracterísticas clinicoepidemiológicas y tendencias en el tratamiento antirretroviral de una cohorte de pacientes con infección por el virus de la inmunodeficiencia humana. Cohorte PISCISPhysician-delivered motivational interviewing to improve adherence and retention in care among challenging HIV-infected patients in Argentina (COPA2): study protocol for a cluster randomized controlled trialBoosting HIV Treatment Options: Good News, New ChallengesHIV drug and supply stock-outs in Latin AmericaProgress of implementation of the World Health Organization strategy for HIV drug resistance control in Latin America and the CaribbeanReply:
P50
Q27316272-85952455-693A-4580-A1B6-907C7EB7D428Q28302032-82990557-6ABB-4488-988C-4AC79FE457C4Q28547790-3A3525F1-394D-44D1-996D-A1A23A320D8BQ33598309-D5AE9E6D-4B2E-4FD6-A0C9-7B23571F3CE1Q33598309-EBA765AD-6F60-477E-9225-B2343D0349A4Q34004816-E5C5F9B8-07B3-40CB-B781-1B1D0BB217A9Q34061945-F2215E5C-D320-4840-9190-786D9F9225C8Q34183261-F3952356-4826-41AF-98F1-1023350D3E0BQ34202804-94F4C3ED-D639-40D2-9AE8-45B62A4AEDE8Q34535811-B5436041-7998-4CAA-985A-B6CDD48A247BQ34920329-E6A75D12-C05C-4E73-BBA2-B24619730BB1Q35023340-893C5608-5F5A-4662-BB90-9C885DDE988EQ35331308-5365CF12-23CE-4C02-BFF6-F23C1CABDACEQ35769177-9258F855-9DAB-431D-8FFF-9A038F99F2DEQ36010191-2BC39160-F9EE-4136-B6EC-CB71528BE7D0Q36422552-320C8F9C-1EF4-488C-ACDF-B78F41CFED3CQ36445691-8A08C72B-48D4-4CBA-9853-CC77B44F504CQ36978926-BFD999BB-F124-4BD8-BD6E-4883507A2E9DQ37665311-E1745A6E-D0AA-43A4-B954-B921C08128A7Q37905675-3162C22B-91C8-47C1-8EF8-52C713CFA390Q38209874-4904674C-D5AE-4EA7-9CFF-2B775F0545C4Q40519226-18F425FA-3B61-4F69-8677-F7F72210AB48Q40865499-C81651B5-4A60-4DA8-9CBE-8688F1DA38BCQ41109220-4667152E-2D9D-418D-8772-861D3096304CQ41160760-6C275ECD-68DC-4989-9D5A-DF616BBC32A9Q41580072-6F32D919-00EF-4200-ACE0-602078B560A6Q42217198-3B820254-4E0B-4617-B65E-CFCA226D2DDAQ42221842-16811F85-FC4F-438E-98D9-5D2E2C4299C4Q42708096-E73D817F-C837-4305-AB8E-D3C20A2250B6Q42930897-4700D850-FDFE-455A-B714-B7028F0E52A7Q45133130-180D25E3-1967-43C8-B060-263BA0675A25Q46218599-DE4FD38B-145D-4466-9442-77293C40577DQ51572179-B99A0733-83DF-4B5B-9EC8-11FC488F482CQ56791543-BD5E77DC-4002-4F3C-AE0D-DB97CB857344Q59780679-0D1DD73F-4A78-476D-B698-AD102FCD0EDEQ61767226-A166A731-FE44-4CDD-826D-92AAD48EF216Q61952013-04876560-04C9-4303-B08D-B893E925652FQ61952072-9DF6C025-0E82-47A7-8FB4-209935448578Q61952097-90B44DCF-877D-4884-A8AF-7BD406AC8D42Q61952113-BAC59207-80F9-4A80-A368-E353E6703718
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Omar Sued
@ast
Omar Sued
@en
Omar Sued
@es
Omar Sued
@sl
type
label
Omar Sued
@ast
Omar Sued
@en
Omar Sued
@es
Omar Sued
@sl
prefLabel
Omar Sued
@ast
Omar Sued
@en
Omar Sued
@es
Omar Sued
@sl
P106
P1153
35228139200
P21
P2798
P31
P496
0000-0001-5818-770X